TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Proclara Biosciences Stock

Proclara Biosciences Stock

proclarabio.comHealthcare / BioTech & PharmaFounded: 2006Funding to Date: $112.79MM

Developer of disease-modifying therapies intended to be used for the treatment of neurodegenerative diseases. The company's therapies develop novel therapies that recognize and target multiple misfolded proteins, enabling clinicians to make a transformative impact on the lives of patients affected by Alzheimer's, Parkinson's and systemic amyloidosis.

Buy or sell Proclara Biosciences stockLearn more about Proclara Biosciences IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Proclara Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Proclara Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Proclara Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Hampus Hillerstrom
Executive Vice President, Co-Founder & Chief Financial Officer
David Michelson MD
Chief Medical Officer & Board Member
Beka Solomon Ph.D
Scientific Founder & Member, Scientific Advisory Board
Jonathan Solomon
Co-Founder and Board Member
Richard Fisher
Chief Executive Officer, President & Board Member

Board Members

David Michelson MD
Jonathan Solomon
Nick Leschly
Paul Goldenheim MD
Valérie Calenda Ph.D
Mérieux Développement
François Valencony
Mérieux Développement
Franz Hefti Ph.D
Kenneth Buckfire
Peter Smedvig
Saira Ramasastry
Daniel Lynch
Hans Schoepflin
Beka Solomon Ph.D
Nico Dosenbach Ph.D
Richard Fisher
Vicki Sato Ph.D

Frequently Asked Questions About Proclara Biosciences’ Stock

plusminus
Can you buy Proclara Biosciences’ stock?
Proclara Biosciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Proclara Biosciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Proclara Biosciences’ stock?
Yes, you can sell stock of a private company like Proclara Biosciences. Forge can help you sell your Proclara Biosciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Proclara Biosciences’ stock price?
Proclara Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Proclara Biosciences’ private market stock price with Forge Data.
plusminus
What is Proclara Biosciences’ stock ticker symbol?
Proclara Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Proclara Biosciences in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

FinSMEs 09/09/2016
Proclara Biosciences Secures $47M in Series E Financing |FinSMEs
Proclara Biosciences, a Cambridge, MA-based biotechnology company developing novel therapies for diseases caused by protein misfolding, secured $47m in Series E financing. The round was led by existing investors including private investors and Merieux Developpement. As part of the Series E financing, Daniel Lynch, an experienced biotechnology executive and a venture partner at Third Rock Ventures, …

Trending Companies

Frequently Asked Questions

Updated on: Apr 25, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.